ライフサイエンスコーパス: proto-oncogene

1 ene homolog (Kras), or overexpression of MYC proto-oncogene.

2 h splicing factor 3 (SRSF3 or SRp20) being a proto-oncogene.

3 gulation, like P53 tumor suppressor and cMYC proto-oncogene.

4 GCM2, suggesting that GCM2 is a parathyroid proto-oncogene.

5 in the rearranged during transfection (RET) proto-oncogene.

6 ative transcription factor may also act as a proto-oncogene.

7 emia through aberrant expression of the EVI1 proto-oncogene.

8 F2alpha regulation is JNK dependent, via jun proto-oncogene.

9 lowing for quantitative analysis of the cMYC proto-oncogene.

10 inhibitors, and overexpression of the c-Myc proto-oncogene.

11 the estrogen receptor coregulator PELP1 is a proto-oncogene.

12 has previously been described as a powerful proto-oncogene.

13 r and therefore generally considered to be a proto-oncogene.

14 t into the categorization of ECT2 as a human proto-oncogene.

15 ss mRNAs including the mRNA encoding the Mos proto-oncogene.

16 driven by an activating mutation in the KIT proto-oncogene.

17 c prostate cancer cells is driven by the MYC proto-oncogene.

18 nent for understanding the role of AGR2 as a proto-oncogene.

19 onmalignant cells was sufficient to activate proto-oncogenes.

20 ted neighborhoods containing prominent T-ALL proto-oncogenes.

21 druplex structures are found in promoters of proto-oncogenes.

22 ain of specific genomic loci known to harbor proto-oncogenes.

23 activate tumor suppressor genes and activate proto-oncogenes.

24 factor activity of the NOTCH1, MYC, and IRF4 proto-oncogenes.

25 ques that regulate the expression of crucial proto-oncogenes.

26 sting and is then inhibited by thymoma viral proto-oncogene 1 (Akt) after feeding.

27 is regulated by the transcription factor ETS proto-oncogene 1 (ETS1) and associated with overexpressi

28 e closely linked E26 transformation-specific proto-oncogene 1 (ETS1) is overexpressed in these FLI1-d

29 inases anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS1) and rearranged during transfecti

30 stic lymphoma kinase (ALK)-rearranged or ROS proto-oncogene 1 (ROS1)-rearranged non-small-cell lung c

31 h pathways dependent or not dependent on ABL proto-oncogene 1 non-receptor tyrosine kinase (c-Abl).

32 ncided with a 4.5-fold increase in ETS1 (ETS proto-oncogene 1) mRNA, suggesting that ETS1 is involved

33 1), KLF4 (Kruppel-like factor 4), Yes1 (YES proto-oncogene 1), and Lox (lysyl oxidase).

34 9 resides within the SH3-binding site of ABL proto-oncogene 1, nonreceptor tyrosine kinase (ABL1), so

35 tibody and a breakpoint cluster region - ABL proto-oncogene 1, nonreceptor tyrosine kinase (BCR-ABL1)

36 Discovered as a proto-oncogene 40 years ago, mutations in KRAS exist in

37 en GTPase, as small GTPases such as RAS-like proto-oncogene A (RALA) or the G12C mutant of KRAS displ

38 Further analyses indicate that the proto-oncogene A-kinase anchoring protein-Lbc is up-regu

39 The RET proto-oncogene, a tyrosine kinase receptor, is widely kn

40 Activity of the proto-oncogene ABL1 is upregulated in FH-deficient kidne

41 gammaretrovirus vectors have caused cellular proto-oncogene activation and leukemia, necessitating th

42 om an index patient and demonstrate that MET proto-oncogene activation is important for tumor growth

43 receptor-bound protein 2 (GRB2) and CRK-like proto-oncogene, adaptor protein (CRKL).

44 Here we report that the proto-oncogene Akt-3/PKBgamma (Akt3) phosphorylates Argo

45 tidyl inositol 3 kinase (PI3K)-thymoma viral proto-oncogene (AKT) inhibitors to kill tumor cells.

46 regulated kinase (ERK) and the thymoma viral proto-oncogene (Akt), followed by activation of the mamm

47 indings establish roles for PLK1 as a potent proto-oncogene and a CIN gene and provide insights for t

48 AGR2 has also been characterized as a proto-oncogene and a potential cancer biomarker.

49 are cell cycle regulators and function as a proto-oncogene and a tumor suppressor respectively in hu

50 Spermatogenic Zip 1 (SPZ1) acts as a proto-oncogene and an upstream regulator of EMT during t

51 and activates an LCR that regulates the BCL6 proto-oncogene and is uniquely required by normal and ma

52 ensin 1-7 and alamandine, which activate MAS proto-oncogene and MAS-related D receptors, respectively

53 esults therefore identify miR-22 as a potent proto-oncogene and suggest that aberrations in the miR-2

54 is study shows that Erk1 can be considered a proto-oncogene and that Erk molecules possess unusual au

55 ed by numerous common integration sites near proto-oncogenes and by increased abundance of clones wit

56 scription factor genes, including MYC family proto-oncogenes and neuroendocrine lineage-specific fact

57 e p53 mutations or undergo amplifications of proto-oncogenes and receptor tyrosine kinases, implicati

58 n-protein interactions, including binding to proto-oncogenes and tumor suppressors to regulate cell d

59 tive splicing, and mRNA expression levels of proto-oncogenes and tumor suppressors.

60 We found repression of MYC proto-oncogene, and up to four-fold reduction in accumul

61 mily 2/3 (SMAD2/3)-dependent manner, and Jun proto-oncogene AP-1 transcription factor subunit (AP-1)

62 r the translation of the mRNAs of JUND (JunD proto-oncogene AP-1 transcription factor subunit) and HI

63 nctions, at least in part, by binding to Jun proto-oncogene, AP-1 transcription factor subunit (cJUN)

64 tor of activated T cells 3 (NFATc3) and FosB proto-oncogene, AP-1 transcription factor subunit (FosB)

65 Mutations or amplification of the MET proto-oncogene are involved in the pathogenesis of sever

66 to constitutive activation of NRAS and KRAS proto-oncogenes are among the most common in human cance

67 The RAS family of proto-oncogenes are among the most commonly mutated gene

68 mation and autoimmunity identified the c-Fos proto-oncogene as a mediator of ER stress responses in e

69 In contrast, the Hras proto-oncogene attenuated the activity of mutant Kras in

70 located near the Casitas B-lineage lymphoma proto-oncogene b gene (CBLB).

71 nstream of KRAS, depletion of RalB (RAS-like proto-oncogene B) and IkappaB kinase-related TANK-bindin

72 Twenty-six patients were tested for a proto-oncogene B-Raf (V600E) (BRAF) mutation (18 had the

73 he best-characterized PP2A substrates is MYC proto-oncogene basic helix-loop-helix transcription fact

74 man primary lymphocytes, and identificed the proto-oncogene BCL2 as a replication stress-induced frag

75 directly activated the transcription of the proto-oncogene BCL6 in normal germinal-center (GC) B cel

76 isms that prevent proteasomal degradation of proto-oncogene beta-catenin (CTNNB1) and its eventual tr

77 This activation required MYC proto-oncogene bHLH transcription factor (c-Myc) and dep

78 The polycomb complex proto-oncogene BMI1 [B lymphoma Mo-MLV insertion region

79 Oncogene-targeted therapy with B-Raf proto-oncogene (BRAF) and mitogen-activated protein kina

80 ing pathway, directed by the oncogenic B-Raf proto-oncogene (BRAF) variant BRAF(V600E), that mediates

81 ich acts independently of canonical melanoma proto-oncogenes, BRAF or NRAS.

82 y displays mutational activation of the KRAS proto-oncogene but, unlike lung cancers expressing mutat

83 t and PH domain 2) isoform 2 is considered a proto-oncogene, but not much is known about AGAP2 gene e

84 shown to be negatively modulated by the MYCN proto-oncogene, but the mechanism of repression was uncl

85 rticular, epigenetic derepression of the RET proto-oncogene by loss of PRC2 recruitment, and activati

86 , activation of otherwise normally repressed proto-oncogenes by promoter demethylation has been infre

87 d ATM-dependent signalling, and identify the proto-oncogene c-Abl as a mediator of this modification.

88 ssays, accompanied by enhanced expression of proto-oncogene C-Fms (C-Fms) and hyper-responsiveness to

89 y and FRET analyses, we demonstrate that the proto-oncogene c-Fos (c-Fos) activates cytoplasmic lipid

90 e shown that co-expression of TAp73 with the proto-oncogene c-Jun can augment cellular growth and pot

91 rrelation between GAPDH upregulation and the proto-oncogene c-jun expression (r = 0.543, P = .003).

92 The proto-oncogene c-Jun is a component of activator protein

93 ain-containing protein, SAMD14, promotes SCF/proto-oncogene c-Kit (c-Kit) signaling, erythroid progen

94 Previously, we have shown that the bZIP proto-oncogene c-Maf regulates expression of alphaA-crys

95 epidermal growth factor receptor (EGFR) and proto-oncogene c-Met (MET), and shunts their trafficking

96 ivity requires binding to its receptors, the proto-oncogene c-Met and heparan sulfate proteoglycan (H

97 oticed transcriptional repression of 5-LO by proto-oncogene c-Myb and conclude that loss of stromal 5

98 Subsequently, upregulation of proto-oncogene c-Myb in TAMs induced a stable transcript

99 blocked at the polymorphic site and that the proto-oncogene c-MYB modulates the release of the pausin

100 und that EPHB4 stimulates the AR by inducing proto-oncogene c-Myc (c-Myc) expression.

101 reconstructed in cell culture, and that the proto-oncogene c-Myc controls the generation of self-ren

102 chromosome 8q24.21 locus, which contains the proto-oncogene c-MYC, long non-coding RNA PVT1, and micr

103 ed sensitivity to dasatinib by targeting the proto-oncogene c-SRC.

104 sociated with the binding of Imatinib to the proto-oncogene c-Src.

105 HPK1 increased the binding of AXL to the Cbl proto-oncogene (c-Cbl); promoted AXL ubiquitination; dec

106 MR) status and somatic mutation in the B-Raf proto-oncogene (c.1799T>A [V600E]; BRAFV600E) or exon 2

107 The proto-oncogene, c-MYC, which declines during SynT differ

108 AnxA2 and SOX2 bind to proto-oncogenes, c-Myc and c-Src, and AnxA2 forms a func

109 The proto-oncogene Casitas b-lineage lymphoma (c-Cbl) is an

110 udies uncover a fine-tuned modulation of the proto-oncogene CCND1 in Ewing sarcoma cells via alternat

111 rp12(-/-) tumors showed higher expression of proto-oncogenes cJun and cMyc and downregulation of tumo

112 For example, the human KRAS proto-oncogene contains a nuclease-hypersensitive elemen

113 ied novel direct targets, including CRK-like proto-oncogene (CRKL) and focal adhesion kinase (FAK).

114 that is predicted to regulate CRKL (CRK-like proto-oncogene, cytoplasmic adaptor) expression.

115 Bcl3 is a putative proto-oncogene deregulated in hematopoietic and solid tu

116 e runt-related transcription factor 1, Fli-1 proto-oncogene, E-twenty-six (ETS) transcription factor

117 PTTG1-dependent expression of the RhoGEF proto-oncogene ECT2 was observed in a number of ccRCC ce

118 The RET (rearranged during transfection) proto-oncogene encodes a receptor tyrosine kinase for me

119 The BCL6 proto-oncogene encodes a transcriptional repressor that

120 The c-abl proto-oncogene encodes a unique protein-tyrosine kinase

121 showed that miR-155 is coexpressed with the proto-oncogene encoding c-MYC in positively selected B c

122 duced by hydrodynamic tail vein injection of proto-oncogenes, enhanced HCC development.

123 ified genes shared by the two cell types are proto-oncogenes ERK2, a component of the ERK/MAPK pathwa

124 The proto-oncogene ets1 is highly expressed in the pre-migra

125 human androgen receptor (AR) coactivator and proto-oncogene expressed at low levels in normal human r

126 epidermal growth factor (EGF)-induced c-FOS proto-oncogene expression in mammalian cells.

127 splayed intense tyrosine hydroxylase and RET proto-oncogene expression in nigral neurons in the patie

128 this method by examining copy number in the proto-oncogene FLT3 and the common V600E point mutation

129 e resulted in an increased expression of the proto-oncogenes FOS and JUN in both cell lines at 72 hr.

130 rough a series of studies, we identified the proto-oncogene fosab (cfos) as a potent miR-101a target

131 Although discovered as the proto-oncogene from which the Abelson leukemia virus der

132 In the skin, the Kras proto-oncogene functions cooperatively with mutant Hras

133 Here, we demonstrate that the proto-oncogene fused in sarcoma (FUS), the chromatin rem

134 on of the growth factor independent 1 family proto-oncogenes, GFI1 and GFI1B.

135 ibromin, a GTPase-activating protein for RAS proto-oncogene GTPase (RAS).

136 s potently drive human cancers, with mutated proto-oncogene GTPase KRAS4B (K-Ras4B) being the most ab

137 The RAS proto-oncogene Harvey rat sarcoma viral oncogene homolog

138 The Myc proto-oncogene has been intensively studied in tumorigen

139 e discovery of potent inhibitors of the BRAF proto-oncogene has revolutionized therapy for melanoma h

140 binger DNA transposons carrying the Myb-like proto-oncogene have expanded dramatically in the Pleurod

141 alpha leads to derepression of the embryonal proto-oncogene Hmga2 in Nkx2-1-negative tumors.

142 nvadopodia component Tks5long, the embryonal proto-oncogene Hmga2, and the epithelial-to-mesenchymal

143 BCL6 is the product of a proto-oncogene implicated in the pathogenesis of human B

144 nslation of the mixed lineage leukemia (MLL) proto-oncogene in an arginine methylation-dependent mann

145 eased copy number and expression of the PIM1 proto-oncogene in genomic data sets of patients with TNB

146 enocarcinoma transcript 1 (MALAT1) acts as a proto-oncogene in hepatocellular carcinoma (HCC).

147 a mechanism by which lncRNA MALAT1 acts as a proto-oncogene in hepatocellular carcinoma, modulating o

148 conventional ErbB2 ones expressing the erbB2 proto-oncogene in mammary epithelium.

149 Mutational activation of the BRAF proto-oncogene in melanocytes reliably produces benign n

150 w mechanistic insights into the role of this proto-oncogene in stem cell differentiation, neuronal ag

151 Amplifications and mutations in the KIT proto-oncogene in subsets of melanomas provide therapeut

152 DeltaNp63alpha, a proto-oncogene in the p53 family of transcription factor

153 is for discovery of epigenetically activated proto-oncogenes in head and neck cancer tumors.

154 nsertions of AAV serotype 2 seem to activate proto-oncogenes in human hepatocellular carcinoma.

155 er cancer development induced by AKT and Ras proto-oncogenes in mice.

156 sites within LMO2, MECOM, and other lymphoid proto-oncogenes in our patients.

157 bacteria integrating into the 5'-UTR of four proto-oncogenes in stomach cancer sequencing data.

158 We identified several putative proto-oncogenes including Arhgap36, Megf10, and Foxr2.

159 Lastly, we identified several new proto-oncogenes, including Foxr2 (encoding forkhead box

160 r BRCA1-deficient MBC by introducing the MET proto-oncogene into a BRCA1-associated breast cancer mod

161 expression strongly correlates with c-jun, a proto-oncogene involved in liver tumorigenesis in human

162 ox R2), which we functionally validated as a proto-oncogene involved in MPNST maintenance.

163 The MYCN proto-oncogene is amplified in a number of advanced-stag

164 Expression of the MECOM (also known as EVI1) proto-oncogene is deregulated by chromosomal translocati

165 Somatic activation of the KRAS proto-oncogene is evident in almost all pancreatic cance

166 mplification and overexpression of erbB2/neu proto-oncogene is observed in 20-30% human breast cancer

167 The MYC proto-oncogene is upregulated, often at the transcriptio

168 30 (involved in membrane transport), and the proto-oncogene JUN, indicate that the Rab1b increase act

169 e transcription factor c-Jun, product of the proto-oncogene JUN, is a key regulator of mitochondrial

170 ents FBJ osteosarcoma oncogene (FOS) and jun proto-oncogene (JUN) to the promoters of a subset of Tol

171 regulation by retinoid X receptor (RXR), jun proto-oncogene (JUN), sine oculis homeobox factor (SIX),

172 onstrate the direct allosteric activation of proto-oncogene kinase Src by GPCR-betaarr complexes in v

173 The proto-oncogene KIT encodes for a tyrosine kinase recepto

174 Activating mutations in the proto-oncogene KRAS are a hallmark of pancreatic ductal

175 RasG, which are highly related to the human proto-oncogene KRas.

176 conjunction with oncogenic activation of the proto-oncogene Kras.

177 >A [V600E]; BRAFV600E) or exon 2 of the KRAS proto-oncogene (KRAS) in the primary tumor with SAR in p

178 Prolonged or enhanced expression of the proto-oncogene Lmo2 is associated with a severe form of

179 mutations in the RET (formerly MEN2A, MEN2B) proto-oncogene located on chromosomal band 10q11.21.

180 The LYN proto-oncogene (LYN) is required for signaling in both d

181 type 2 angiotensin II receptor (AT(2)R), the proto-oncogene Mas receptor and the Mas-related G protei

182 iption factor binding to the promoter of the proto-oncogene MDM2, and to influence cancer risk.

183 xemplified by antibodies, an E3 ligase, MDM2 proto-oncogene (MDM2), and protease (SplB from Staphyloc

184 The proto-oncogene MET receptor tyrosine kinase overcomes th

185 signaling uses lateral activation of the met proto-oncogene (MET) through SRC proto-oncogene nonrecep

186 The MET proto-oncogene (MET) tyrosine kinase receptor promotes m

187 As potent proto-oncogenes, models of MYC family function have been

188 These include the signaling gene TGFBR1, the proto-oncogene MYB as well as many immune-related genes

189 echanistically, ERK5 directly stabilized the proto-oncogene MYC at the protein level.

190 strong, haplotype-specific activation of the proto-oncogene MYC by the integrated HPV-18 genome appro

191 Tumour suppressor p53 or proto-oncogene MYC is frequently altered in squamous car

192 Seminal studies have shown that the proto-oncogene MYC promotes metabolic reprogramming by a

193 vates myofibroblast cell identity genes, the proto-oncogene Myc, and an array of genes encoding pro-i

194 lso been implicated in the repression of the proto-oncogene Myc, but the mechanism has remained uncle

195 While the c-Myc proto-oncogene (Myc) is required for intestinal phenotyp

196 We investigated the activities of the RELB proto-oncogene NF-kappaB subunit in human cholangiocytes

197 ated ITG-dependent focal adhesion kinase/Src proto-oncogene non-receptor tyrosine kinase signaling.

198 uter mitochondrial membrane 34) and SRC (SRC proto-oncogene, non-receptor tyrosine kinase).

199 of the met proto-oncogene (MET) through SRC proto-oncogene nonreceptor tyrosine kinase to maximize c

200 We previously identified SRC proto-oncogene, nonreceptor tyrosine kinase (c-Src), as

201 domain and is directly phosphorylated by SRC proto-oncogene, nonreceptor tyrosine kinase (SRC) at Tyr

202 Here, we show that SRC proto-oncogene, nonreceptor tyrosine kinase (SRC) is an

203 ing of late endosomes allows delivery of SRC proto-oncogene, nonreceptor tyrosine kinase (SRC) to the

204 Dsc3 and anti-SPCA1 AuAbs also activated SRC proto-oncogene, nonreceptor tyrosine kinase (SRC).

205 The proto-oncogenes NTRK1/2/3 encode the tropomyosin recepto

206 lated neighborhoods, we investigated whether proto-oncogenes occur within these structures and whethe

207 Myc is a proto-oncogene often found to be deregulated in many can

208 n be caused by germline mutations of the RET proto-oncogene or occurs as a sporadic form.

209 en initiated by genetic events that activate proto-oncogenes or inactivate tumor-suppressor genes.

210 Here, we identify the protein kinase and proto-oncogene PIM3 as being repressed downstream of mTO

211 ayed highly significant up-regulation of the proto-oncogene pleomorphic adenoma gene 1 (PLAG1), sugge

212 tes expression of CDKN2a/p16(INK4a) and BMI1 proto-oncogene polycomb ring finger (BMI1), with the lat

213 ver, whether the human mTOR gene itself is a proto-oncogene possessing tumorigenicity has not been fi

214 We propose that combined control of proto-oncogene product levels and proteins involved in D

215 subunits and "small" G proteins, such as the proto-oncogene product RAS, which contains a single subu

216 SF) and its receptor, the product of the MET proto-oncogene, promote invasion and metastasis of tumor

217 pe was observed by overexpressing c-Myc (Myc proto-oncogene protein), a downstream target of Pim kina

218 ine phosphatase (PTP) SHP2 is encoded by the proto-oncogene PTPN11 and is a ubiquitously expressed ke

219 The proto-oncogene PTTG and its binding partner PBF have bee

220 el in Drosophila, oncogenic mutations of the proto-oncogene Ras (Ras(V12)) maintain tumorous cells in

221 tiated hepatocyte growth factor (HGF) to MET proto-oncogene receptor tyrosine kinase (c-Met) autocrin

222 nfluences the prognostic significance of KIT proto-oncogene receptor tyrosine kinase (KIT) and platel

223 aberrant hepatocyte growth factor (HGF)/MET proto-oncogene receptor tyrosine kinase (MET) and Wnt/be

224 , we report that signalling engaging the MET proto-oncogene receptor tyrosine kinase/focal adhesion k

225 Resistance to approved inhibitors of KIT proto-oncogene, receptor tyrosine kinase (KIT), and plat

226 GDNF family receptor alpha like (GFRAL)-Ret proto-oncogene (RET) signaling complex in brainstem neur

227 , with the most frequent variants in the ret proto-oncogene (RET).

228 ned for an alternatively spliced exon in the proto-oncogene RON and determine the functional units th

229 The proto-oncogene ROS1 encodes a receptor tyrosine kinase w

230 ncreased interaction of the RAS ITD with Raf proto-oncogene Ser/Thr kinase (RAF), leading to increase

231 roscopy, we demonstrated that KRAS and Raf-1 proto-oncogene Ser/Thr kinase (RAF1) domains interact wi

232 the presence of inhibitors targeting the RAF proto-oncogene Ser/Thr protein kinase (RAF) and MAPK/ERK

233 Class 3 mutations in B-Raf proto-oncogene, Ser/Thr kinase (BRAF), that result in ki

234 of the Ras-binding domain (RBD) of the C-Raf proto-oncogene, Ser/Thr kinase (CRAF).

235 g by dimerizing with and activating WT C-Raf proto-oncogene, Ser/Thr kinase (CRAF).

236 r of cytokine signaling 2/3 (Socs2/3); Pim-1 proto-oncogene, Ser/Thr kinase (Pim1); and Fms-related t

237 endent release of insulin, activation of RAF proto-oncogene, Ser/Thr kinase (Raf)-mitogen-activated p

238 the identification of clients, such as Raf-1 proto-oncogene, Ser/Thr kinase (RAF1), that are particul

239 ion, with the latter being mediated by Raf-1 proto-oncogene, Ser/Thr kinase (RAF1).

240 The B-Raf proto-oncogene serine/threonine kinase (BRAF) gene is th

241 pG island methylator phenotype (CIMP), B-Raf proto-oncogene serine/threonine kinase (BRAF) mutation,

242 ard, which in turn gradually suppressed RAF1 proto-oncogene serine/threonine kinase (RAF1)/ERK signal

243 Here, we report the efficacy of the Raf proto-oncogene serine/threonine protein kinase (RAF) inh

244 ted HRAS(G12V) with its effector protein RAF proto-oncogene serine/threonine protein kinase 1 (RAF1).

245 The protein kinase B-Raf proto-oncogene, serine/threonine kinase (BRAF) is an onc

246 se methylesterase 1 (PME-1), and SET nuclear proto-oncogene (SET) that often are deregulated in cance

247 errant HGF-MET (hepatocyte growth factor-met proto-oncogene) signaling activation via interactions wi

248 variation in ten individuals with SGS in the proto-oncogene SKI, a known repressor of TGF-beta activi

249 bited antifibrotic Sloan-Kettering Institute proto-oncogene (Ski) and Ski-related novel gene, non-Alu

250 ical T-cell signaling pathway, including LCK proto-oncogene SRC family tyrosine kinase (LCK), LYN pro

251 cogene SRC family tyrosine kinase (LCK), LYN proto-oncogene SRC family tyrosine kinase (LYN), zeta ch

252 Fibroblasts transformed by the proto-oncogene Src form individual invadopodia that can

253 We showed that proto-oncogene Src kinase and Akt are direct targets of

254 ing enzyme, PIPKIgammai2, functions with the proto-oncogene Src, to regulate oncogenic signaling.

255 owth of tumor cells in coordination with the proto-oncogene Src.

256 Interactions of LCK proto-oncogene, SRC family tyrosine kinase (LCK), and th

257 se linker by a SRC family kinase such as LYN proto-oncogene, SRC family tyrosine kinase (LYN).

258 eport that the RNA-binding protein (RBP) and proto-oncogene SRSF1 (serine and arginine-rich splicing

259 a hallmark of KS by unique activation of the proto-oncogene STAT3, coupled with MK2-mediated inactiva

260 JunD (Jund proto-oncogene subunit), a member of the AP-1 (activator

261 ation of hepatocellular carcinoma-associated proto-oncogenes such as c-Jun and associated transcripti

262 this in part by increasing the expression of proto-oncogenes such as MYC and cyclins.

263 errantly expressed both stem cell-associated proto-oncogenes, such as Lmo2, Hhex, Lyl1, and Kit, whic

264 WWP1 appears to be a direct MYC (MYC proto-oncogene) target gene and was critical for MYC-dri

265 MET is a known proto-oncogene that acts through a diverse set of signal

266 53 with a gain of function (GOF), creating a proto-oncogene that contributes to tumorigenesis, tumor

267 Together, we conclude that eIF3i is a proto-oncogene that drives colon oncogenesis by translat

268 PIKE-A, a proto-oncogene that is one of the important components o

269 ge of Mer tyrosine receptor kinase (MerTK, a proto-oncogene that plays a critical role in phagocytosi

270 as-like DNA in the 5'-UTR and 3'-UTR of four proto-oncogenes that are up-regulated in their transcrip

271 ascribed to PDAC with mutations in the KRAS2 proto-oncogene thought to be an early event in the progr

272 ed in hepatocellular carcinoma and acts as a proto-oncogene through Wnt pathway activation and induct

273 several cancer/testis antigens and the c-kit proto-oncogene throughout multiple recurrences.

274 cause NS and expand the involvement of RRAS2 proto-oncogene to rare germline disorders.

275 f escape whereby tumor cells upregulated the proto-oncogene transcriptional regulators c-MYC and YAP1

276 e, to investigate the interplay between IGH@ proto-oncogene translocation and IGH allelic exclusion,

277 IGH@ proto-oncogene translocation is a common oncogenic event

278 Aberrant expression of BCL11B or proto-oncogene translocation to the vicinity of BCL11B c

279 d a novel oncogenic fusion involving the MER proto-oncogene tyrosine kinase (MERTK) and discovered a

280 C-MER proto-oncogene tyrosine kinase (MERTK) is a receptor tyr

281 hagocytosis due to a deficiency of the c-Mer proto-oncogene tyrosine kinase (Mertk) nonetheless conta

282 We now show that signaling through the Mer proto-oncogene tyrosine kinase (MerTK) receptor in cultu

283 Other studies have shown elevated proto-oncogene tyrosine kinase (SRC) activity in invasiv

284 Proto-oncogene tyrosine-protein kinase (Src) was identif

285 (miR200c, miR20b, and miR31through cellular proto-oncogene tyrosine-protein kinase Src (cSrc)), resp

286 ar alterations of YES1, a member of the SRC (proto-oncogene tyrosine-protein kinase Src) family kinas

287 ORC2 targets included focal adhesion kinase, proto-oncogene tyrosine-protein kinase Src, and caveolin

288 phorylated by the tyrosine kinases p60c-Src (proto-oncogene tyrosine-protein kinase) and the proline-

289 ng that the HER2 oncogene, as opposed to the proto-oncogene, upregulates expression of the E2F2 trans

290 Here the activity of the proto-oncogene Vav2, a GEF for Rac1, RhoA, and Cdc42, is

291 in leukemogenesis by causing deregulation of proto-oncogenes via relocation of cryptic regulatory DNA

292 3-14 region, and more specifically, the CDK4 proto-oncogene was highly amplified.

293 Expression of the c-Myc proto-oncogene was increased in proliferating cytotropho

294 A set of glioma proto-oncogenes was enriched among the transcriptomic co

295 ABL1 is a proto-oncogene well known as part of the fusion gene BCR

296 hat it is cleaved and interacts with the JUN proto-oncogene, which forms part of the activator protei

297 emonstrate that overexpression of eIF4E, the proto-oncogene whose activity is specifically inhibited

298 These results suggest that MAGE-A11 is a proto-oncogene whose increased expression in prostate ca

299 rentiation, and were established early on as proto-oncogenes, with aberrant expression linked to tumo

300 evious results, we hypothesized that the MYC proto-oncogene would show differential expression in pRC